Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 4,173 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,173 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $4.88, for a total value of $20,364.24. Following the transaction, the chief executive officer now directly owns 740,019 shares in the company, valued at $3,611,292.72. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Cryoport Stock Performance

Shares of NASDAQ CYRX opened at $6.65 on Wednesday. The stock’s fifty day moving average price is $7.19 and its two-hundred day moving average price is $7.54. The firm has a market cap of $328.72 million, a price-to-earnings ratio of -1.97 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport, Inc. has a one year low of $4.58 and a one year high of $20.11.

Cryoport (NASDAQ:CYRX) last released its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the company posted ($0.29) earnings per share. On average, equities analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current year.

Institutional Trading of Cryoport

Institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after buying an additional 2,120 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cryoport during the 4th quarter worth $51,000. Avanza Fonder AB bought a new stake in shares of Cryoport during the 4th quarter worth $64,000. Quarry LP bought a new stake in shares of Cryoport during the 4th quarter worth $69,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Cryoport during the 3rd quarter worth $82,000. 92.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim started coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.